%0 Generic
%A Sanchez, R
%A Ayala, R
%A Alonso, RA
%A Ribera, J
%A García, O
%A Mercadal, S
%A Montesinos, P
%A Martino, R
%A Barba, P
%A González-Campos, J
%A Barrios, M
%A Lavilla, E
%A Gil, C
%A Bernal, T
%A Escoda, L
%A Abella, E
%A Amigo, ML
%A Moreno, MJ
%A Bravo, P
%A Guàrdia, R
%A Hernández-Rivas, JM
%A García-Guiñón, A
%A Piernas, S
%A Ribera, JM
%A Martínez-López, J
%T Pattern of CNS relapse in acute lymphoblastic leukemia BCR-ABL positive, the importance of characterization of ABL1 mutations in cerebrospinal fluid.
%D 2016
%@ 0390-6078
%U http://hdl.handle.net/10668/2444
%X He incidence of central nervous system (CNS) relapse among; patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) is 8-17%. Although tyrosine-kinase inhibitors (TKI), especially imatinib, are included in; the first-line treatment in these patients, their concentration in CNS is too low; to effectively prevent CNS relapse, making CNS prophylaxis mandatory. Aims: To study the frequency, predictors and evolution of BCR-ABL positive; ALL patients with CNS relapse in two consecutive clinical trials of the PETHEMA; group using imatinib and chemotherapy. As secondary objective we proposed; the introduction of a new method for the study of variants of uncertain; significance (VUS) in kinase domain of the BCR-ABL from cDNA of cerebrospinal; fluid (CSF) blasts, in order to adapt the TKI used in relapse according; to the clonal evolution from bone marrow (BM) to CSF cells.
%K Médula ósea
%K Evolución clonal
%K ADN complementario
%K Proteínas de fusión bcr-abl
%K Humanos
%K Mesilato de imatinib
%K Incidencia
%K Masculino
%K Sistema nervioso
%K Leucemia-linfoma linfoblástico de células precursoras
%K Recurrencia
%K Tirosina
%~